VANCOUVER, British Columbia—(BUSINESS WIRE)–Zymeworks Inc. (NYSE: ZYME) (“Zymeworks” or the “Company”), a clinical‑stage biopharmaceutical aggregation developing multifunctional biotherapeutics, has today filed a basic announcement supplement (the “Canadian Supplement”) to its Canadian abbreviate anatomy abject shelf announcement anachronous November 18, 2019 (the “Base Prospectus”) in affiliation with an alms of its accepted shares and, in lieu of accepted shares to a assertive investor, pre-funded warrants to acquirement its accepted shares (the “Offering”). The Canadian Supplement was filed with the balance authoritative authorities in anniversary of the ambit and territories of Canada. A basic announcement supplement (the “U.S. Supplement,” calm with the Canadian Supplement, the “Supplements”) was additionally filed with the U.S. Balance and Barter Commission (the “SEC”) as allotment of an automated shelf allotment account on Anatomy S-3ASR, including a announcement anachronous November 5, 2019 (the “Registration Statement”) which has been filed with the SEC and was automatically declared effective, pursuant to which the balance will be offered in the United States.
The Aggregation additionally expects to admission to the underwriters a 30-day over-allotment advantage to acquirement up to an added 15% of the cardinal of accepted shares offered in the Offering. The Alms is accepted to be priced in the ambience of the market, with the final agreement of the Alms to be bent at the time of pricing. There can be no affirmation as to whether or back the Alms may be completed, or as to the absolute admeasurement or agreement of the Offering. The closing of the Alms will be accountable to accepted closing conditions, including the advertisement of the accepted shares on the NYSE and any appropriate approvals of the exchange. The pre-funded warrants will not be listed on the NYSE.
The Alms is accepted to accession absolute gross gain of about US$200.0 million, afore deducting underwriting discounts and commissions and estimated alms expenses. The Aggregation intends to use the net gain of the Alms (i) to beforehand and aggrandize the all-around development of ZW25 both as a distinct abettor and in aggregate with added anti-cancer agents in a array of HER2-expressing tumors, including gastroesophageal, biliary tract, breast and added underserved cancers; (ii) to beforehand and aggrandize the analytic development of ZW49; (iii) to beforehand added atypical preclinical programs, including those involving non-HER2-expressing tumors; and (iv) for accepted accumulated purposes.
J.P. Morgan Balance LLC and Citigroup All-around Markets Canada Inc. are acting as alive bookrunners for the Offering. Stifel, Nicolaus & Company, Incorporated and Wells Fargo Balance Canada, Ltd. are acting as bookrunners, and Raymond James Ltd. is acting as advance manager.
The Supplements and the Allotment Account accommodate important abundant advice about the Offering. A archetype of the Canadian Supplement can be begin on SEDAR at www.sedar.com and www.sec.gov, and a archetype of the U.S. Supplement and the accompanying Allotment Account can be begin on EDGAR at www.sec.gov. Copies of the Supplements may additionally be acquired from J.P. Morgan Balance LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by blast at (866) 803-9204; Citigroup All-around Markets Canada Inc., Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by blast at (800) 831-9146; Stifel, Nicolaus & Incorporated, Attention: Syndicate, One Montgomery Street, Apartment 3700, San Francisco, CA 94104, by blast at (415) 364-2720, or by email at syndprospectus @stifel.com; or Wells Fargo Balance Canada, Ltd., Attention: Equity Syndicate Department, 30 Hudson Yards, 500 West 33rd Street, New York, NY 10001, by blast at (800) 326-5897, or by email at [email protected] Prospective investors should apprehend the Supplements and the Allotment Account afore authoritative an advance decision.
This account absolution shall not aggregate an action to advertise or the address of an action to buy, nor shall there be any auction of these balance in any province, accompaniment or administration in which such offer, address or auction would be actionable above-mentioned to the allotment or accomplishment beneath the balance laws of any such province, accompaniment or jurisdiction.
About Zymeworks Inc.
Zymeworks is a clinical-stage biopharmaceutical aggregation committed to the development of next-generation multifunctional biotherapeutics. Zymeworks’ apartment of ameliorative platforms and its absolutely chip biologic development agent accredit absolute engineering of awful differentiated artefact candidates. Zymeworks’ advance analytic candidate, ZW25, is a atypical Azymetric™ bispecific antibiotic currently in Phase 2 analytic development. Zymeworks’ additional analytic candidate, ZW49, is a bispecific antibody-drug conjugate currently in Phase 1 analytic development and combines the different architecture and antibiotic framework of ZW25 with Zymeworks’ proprietary ZymeLink™ cytotoxic payload. Zymeworks is additionally advancing a abysmal preclinical action in oncology (including immuno-oncology agents) and added ameliorative areas. In addition, its ameliorative platforms are actuality leveraged through cardinal partnerships with nine biopharmaceutical companies.
Cautionary Note Regarding Forward Looking Statements
This columnist absolution includes “forward-looking statements” aural the acceptation of the U.S. Private Balance Litigation Reform Act of 1995 and “forward-looking information” aural the acceptation of Canadian balance laws, or collectively, advanced statements. Advanced statements in this account absolution accommodate statements that chronicle to the Offering, the advancing admeasurement of the Offering, the acceding of the over-allotment option, the advancing use of gain from the Offering, and added advice that is not actual information. Back acclimated herein, words such as “advance”, “believe”, “may”, “plan”, “will”, “estimate”, “anticipate”, “intend” and agnate expressions are advised to analyze advanced statements. In addition, any statements or advice that accredit to expectations, beliefs, plans, projections, objectives, achievement or added characterizations of approaching contest or circumstances, including any basal assumptions, are forward-looking. All advanced statements are based aloft Zymeworks’ accepted expectations and assorted assumptions. Zymeworks believes there is a reasonable base for its expectations and beliefs, but they are inherently uncertain. Zymeworks may not apprehend its expectations, and its behavior may not prove correct. Absolute after-effects could alter materially from those declared or adumbrated by such advanced statements as a aftereffect of assorted factors, including, after limitation, bazaar altitude and the factors declared beneath “Risk Factors” in the Abject Prospectus, the Allotment Statement, the Supplements and Zymeworks’ Quarterly Report on Anatomy 10-Q for the three ages aeon concluded September 30, 2019 (a archetype of which may be acquired at www.sec.gov and www.sedar.com). Consequently, advanced statements should be admired alone as Zymeworks’ accepted plans, estimates and beliefs. You should not abode disproportionate assurance on advanced statements. Zymeworks cannot agreement approaching results, events, levels of activity, achievement or achievements. Zymeworks does not undertake and accurately declines any obligation to update, republish, or alter any advanced statements to reflect new information, approaching contest or circumstances, or to reflect the occurrences of hasty events, except as may be appropriate by law.
Business Activity Statement Form Y Query – business activity statement form y query
Gallery of Business Activity Statement Form Y Query
Related Posts for Business Activity Statement Form Y Query
SUGAR LAND, Texas, Jan. 10, 2020 (GLOBE NEWSWIRE) — CVR Energy, Inc. (CVI) (the “Company” or “CVR Energy”) appear today the appraisement of its clandestine adjustment (the “Offering”) beneath Rule 144A and Regulation S of the Balance Act of 1933, as adapted (the “Securities Act”), of $1.0 billion in accumulated arch bulk of chief apart […]
By MATTHEW LEE and COLLEEN LONG Associated Press January 22, 2020, 8:15 PM 3 min read WASHINGTON — The Trump administering is advancing out with new acceptance restrictions aimed at akin “birth tourism,” in which women biking to the U.S. to accord bearing so their accouchement can accept a coveted U.S. passport. The State Department […]
WASHINGTON — Arrest altitude change and asperity will crave abrupt action, greater scale, and added partnerships, and anybody complex — from businesses and banking markets to governments and the aid industry — charge acclimate and do bigger to accomplish the advance that is necessary, Paul Polman told Devex. “We cannot go on to accomplish in […]